These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28728495)

  • 21. National survey of quality assurance activities for pharmacy-prepared sterile products in hospitals.
    Crawford SY; Narducci WA; Augustine SC
    Am J Hosp Pharm; 1991 Nov; 48(11):2398-413. PubMed ID: 1746573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Community pharmacists' knowledge of and attitudes toward oral chemotherapy.
    O'Bryant CL; Crandell BC
    J Am Pharm Assoc (2003); 2008; 48(5):632-9. PubMed ID: 18826902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective.
    Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B
    J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Injectable-antineoplastic-drug practices in Michigan hospitals.
    Cohen IA; Newland SJ; Kirking DM
    Am J Hosp Pharm; 1987 May; 44(5):1096-105. PubMed ID: 3605120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders.
    Crandell BC; Bates JS; Grgic T
    J Oncol Pharm Pract; 2018 Dec; 24(8):609-616. PubMed ID: 28776478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Work practice and some adverse health effects in nurses handling antineoplastic drugs.
    Krstev S; Perunicić B; Vidaković A
    Med Lav; 2003; 94(5):432-9. PubMed ID: 14619181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of evidence-based practice among hospital pharmacists in Saudi Arabia: attitude, awareness, and practice.
    Al-Jazairi AS; Alharbi R
    Int J Clin Pharm; 2017 Aug; 39(4):712-721. PubMed ID: 28608329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Errors detected in pediatric oral liquid medication doses prepared in an automated workflow management system.
    Bledsoe S; Van Buskirk A; Falconer RJ; Hollon A; Hoebing W; Jokic S
    Am J Health Syst Pharm; 2018 Feb; 75(3):127-131. PubMed ID: 29371193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment.
    Yoshida J; Tei G; Mochizuki C; Masu Y; Koda S; Kumagai S
    Ann Occup Hyg; 2009 Mar; 53(2):153-60. PubMed ID: 19261696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing an Intervention to Decrease Healthcare Workers' Exposure to Antineoplastic Agents.
    Graeve C; McGovern PM; Arnold S; Polovich M
    Oncol Nurs Forum; 2017 Jan; 44(1):E10-E19. PubMed ID: 27991608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Society of Hospital Pharmacists of Australia: are you at risk?
    Aust Hosp; 1981 Jul; (54):4-5. PubMed ID: 10254354
    [No Abstract]   [Full Text] [Related]  

  • 33. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.
    Favier B; Labrosse H; Gilles-Afchain L; Cropet C; Perol D; Chaumard N; Latour JF; Hild P
    J Oncol Pharm Pract; 2012 Mar; 18(1):37-45. PubMed ID: 21422148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit.
    Crespo A; Tyszka M
    J Oncol Pharm Pract; 2017 Jun; 23(4):243-248. PubMed ID: 26911478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of guidelines and current practices for safe handling of antineoplastic and other hazardous drugs used in 24 countries.
    Mathias PI; MacKenzie BA; Toennis CA; Connor TH
    J Oncol Pharm Pract; 2019 Jan; 25(1):148-162. PubMed ID: 28841099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Auditing sterile compounding competency with video observation.
    Connor TK; Lim JH; Hinton TM
    Am J Health Syst Pharm; 2017 Aug; 74(16):1218-1219. PubMed ID: 28790073
    [No Abstract]   [Full Text] [Related]  

  • 37. [Continuous training program for technicians handling antineoplastic drugs and occupational exposure risk].
    Dussart C; Favier B; Gilles L; Camal I; Almeras D; Latour JF; Grelaud G
    Bull Cancer; 2008 Sep; 95(9):821-2. PubMed ID: 18829414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nurses' protective measures during chemotherapy preparation and administration in Turkey*.
    Rizalar S; Tural E; Altay B
    Int J Nurs Pract; 2012 Feb; 18(1):91-8. PubMed ID: 22257336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compounding practices in Iran.
    Goodarzi N; Niknam S; Akbarzadeh T; Gholami K
    Int J Pharm Compd; 2014; 18(2):112-6. PubMed ID: 24881113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.